Low-Dose Naltrexone and Gastrointestinal Health

Mechanisms, Clinical Evidence, and Integrative Applications

Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine

Integrative & Functional Medicine Physician

Abstract

Low-dose naltrexone (LDN), administered at doses of approximately 0.5 to 4.5 mg daily, has emerged as a versatile off-label therapy with proposed immunomodulatory, anti-inflammatory, prokinetic, and analgesic properties. The gastrointestinal (GI) tract is a biologically plausible therapeutic target for LDN because of the dense expression of opioid receptors on enteric neurons and mucosal immune cells, the central role of Toll-like receptor 4 (TLR4) signaling in mucosal inflammation, the importance of enteric glial activation in visceral hypersensitivity, and the influence of the opioid growth factor (OGF)–OGF receptor (OGFr) axis on epithelial proliferation and tissue repair. This chapter synthesizes the relevant gastrointestinal physiology and pharmacology of LDN and reviews the clinical evidence for its use in inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), small intestinal bacterial overgrowth (SIBO), dysbiosis-related dysmotility, and gut–brain axis disorders. Available data come predominantly from small randomized controlled trials, prospective cohort studies, retrospective case series, and a national prescription-database study, and have been summarized in a Cochrane systematic review. While the current evidence base remains preliminary and the overall quality of evidence has been judged low because of imprecision and small sample sizes, the consistency of clinical and mechanistic findings, combined with a favorable safety profile, supports continued investigation of LDN as a low-risk adjunctive therapy within an integrative model of gastrointestinal care. The chapter closes with practical clinical guidance on patient selection, dosing, titration, monitoring, and combination with conventional therapy.

1. Introduction

Over the past two decades, low-dose naltrexone (LDN) has moved from a niche curiosity in integrative medicine to a credible candidate therapy in a wide range of chronic inflammatory, autoimmune, and pain-related disorders. Although naltrexone hydrochloride was originally approved by the United States Food and Drug Administration at a standard oral dose of 50 mg daily for the treatment of opioid and alcohol dependence, the drug exhibits qualitatively distinct pharmacodynamic effects when administered at substantially lower doses, typically in the range of 0.5 to 4.5 mg per day. At these doses, brief opioid receptor blockade appears to induce a compensatory rebound in endogenous opioid signaling, modulate glial cell activation, and antagonize neuroinflammatory pathways mediated through Toll-like receptor 4 (TLR4) and the opioid growth factor (OGF)–OGF receptor (OGFr) axis (Younger, Parkitny, & McLain, 2014; Patten, Schultz, & Berlau, 2018).

The gastrointestinal tract is an especially compelling target for LDN therapy. The gut is simultaneously a digestive, immune, neural, and endocrine organ. Approximately seventy percent of the body’s lymphoid tissue resides within the gut-associated lymphoid tissue (GALT), and the enteric nervous system (ENS) contains hundreds of millions of neurons capable of regulating motility, secretion, and visceral sensation largely independently of the central nervous system (Furness, 2012). The intestinal epithelium is the largest interface between the host and the external environment, and the resident microbiome interacts continuously with mucosal immune cells through pattern recognition receptors and microbial metabolites. Each of these systems intersects with mechanisms that LDN is hypothesized to influence.

Mechanistic studies, small randomized controlled trials, prospective cohort studies, retrospective case series, and a national prescription database analysis collectively suggest that LDN may favorably influence intestinal permeability, visceral hypersensitivity, mucosal healing, immune activation, and gut–brain signaling. Clinical interest is most developed in Crohn’s disease, where early trials demonstrated meaningful symptomatic improvement and endoscopic healing. Smaller signals have been reported in ulcerative colitis, irritable bowel syndrome, small intestinal bacterial overgrowth, functional dysmotility, and gut–brain axis disorders. A Cochrane systematic review concluded that the available evidence in Crohn’s disease is suggestive but limited, with overall low quality due to small sample sizes and methodological imprecision (Parker, Nguyen, Segal, MacDonald, & Chande, 2018).

This chapter integrates the relevant gastrointestinal physiology, pharmacology of LDN, mechanistic findings, and clinical evidence, and concludes with practical guidance for clinicians considering LDN as part of integrative gastrointestinal care. The discussion is framed within current evidence quality, acknowledging both the promise and the limitations of the existing literature.

2. The Gastrointestinal Tract as an Immunoneural Organ

Understanding the proposed therapeutic effects of LDN in the gut requires appreciation of the gastrointestinal tract as an integrated immune, neural, microbial, and epithelial system. Each of these systems is influenced by endogenous opioid signaling, neuroinflammatory pathways, and the host–microbiome interface—the very pathways through which LDN is thought to act.

2.1. Gut-associated lymphoid tissue and mucosal immunity

The GALT comprises the largest aggregation of immune tissue in the body, including Peyer’s patches, isolated lymphoid follicles, mesenteric lymph nodes, and a dense population of dendritic cells, macrophages, plasma cells, and T and B lymphocytes scattered throughout the lamina propria (Abraham & Cho, 2009). The GALT serves the dual function of tolerating commensal organisms and dietary antigens while mounting protective immune responses against pathogens. Dysregulation of this balance, sometimes described as a loss of oral tolerance, contributes to the pathogenesis of IBD, food sensitivities, and a range of immune-mediated disorders.

2.2. The enteric nervous system and gut–brain axis

The enteric nervous system is often described as the “second brain.” Composed of two principal plexuses—the myenteric (Auerbach’s) plexus regulating motility, and the submucosal (Meissner’s) plexus regulating secretion and blood flow—the ENS exchanges bidirectional signals with the central nervous system through the vagus nerve, spinal afferents, and the sympathetic chain (Furness, 2012). The ENS contains nearly all the major neurotransmitters found in the brain, including serotonin, dopamine, acetylcholine, gamma-aminobutyric acid, and opioid peptides. Disruption of ENS function and gut–brain signaling underlies many functional gastrointestinal disorders, including IBS, functional dyspepsia, and chronic abdominal pain syndromes.

2.3. The intestinal barrier and tight junction integrity

The intestinal epithelium forms a single-cell-thick selectively permeable barrier between the host and a luminal environment containing trillions of microorganisms and dietary antigens. Barrier integrity depends on tight junction proteins—including the claudin family, occludin, and zonula occludens proteins—which dynamically regulate paracellular permeability. Disruption of these junctions, colloquially termed “leaky gut” or increased intestinal permeability, permits translocation of bacterial products such as lipopolysaccharide (LPS) into the lamina propria and systemic circulation, driving immune activation and low-grade chronic inflammation. Increased permeability has been documented in IBD, celiac disease, IBS, nonalcoholic fatty liver disease, and several autoimmune and neuroinflammatory conditions.

2.4. Pattern recognition receptors and innate immunity

Intestinal epithelial cells, dendritic cells, macrophages, and enteric glia all express pattern recognition receptors, including the Toll-like receptors (TLRs). TLR4 is of particular interest in the context of LDN. TLR4 recognizes microbial LPS and a variety of damage-associated molecular patterns, initiating intracellular signaling through MyD88 and TRIF adaptors and activating the nuclear factor-kappa B (NF-κB) pathway. Excessive or dysregulated TLR4 signaling drives mucosal inflammation, cytokine release (including tumor necrosis factor-alpha [TNF-α] and interleukin-6 [IL-6]), oxidative stress, and recruitment of inflammatory cells (Hutchinson et al., 2008). Persistent TLR4 activation has been implicated in increased intestinal permeability, dysbiosis, visceral hypersensitivity, and central sensitization.

2.5. The microbiome and host interactions

The gut microbiome, comprising trillions of bacteria, archaea, fungi, and viruses, interacts continuously with the host through mucosal immune cells, short-chain fatty acid signaling, bile acid metabolism, and direct neuroendocrine pathways. Dysbiosis—a disruption of microbial diversity and composition—has been implicated in IBD, IBS, obesity, metabolic syndrome, autoimmune disease, and a growing list of neuroinflammatory disorders. Microbial signals influence enteric neuronal function, glial activation, epithelial barrier integrity, and the maturation of mucosal immune responses. Therapies that modulate inflammation, motility, or barrier function therefore inevitably interact with the microbiome, either directly or indirectly.

3. Pharmacology of Low-Dose Naltrexone

3.1. From standard- to low-dose: a paradoxical pharmacology

Naltrexone is a competitive antagonist at the μ-, κ-, and δ-opioid receptors. At conventional doses of 50 mg or more daily, sustained receptor blockade prevents the euphoric and reinforcing effects of opioids and alcohol, and the drug is therefore used in opioid use disorder and alcohol dependence. At substantially lower doses, however, naltrexone produces qualitatively different effects. Following oral administration of 1 to 4.5 mg, the drug is rapidly absorbed and produces transient opioid receptor blockade lasting approximately four to six hours before clearance. This brief blockade is thought to trigger compensatory upregulation of endogenous opioids, including β-endorphin and met-enkephalin, and to enhance receptor sensitivity following dissipation of the blockade (Younger et al., 2014; Patten et al., 2018).

Donahue, McLaughlin, and Zagon (2011) demonstrated in tissue culture models that brief opioid receptor blockade by naltrexone inhibited cell proliferation in human cancer cell lines representative of ovarian, pancreatic, colorectal, and squamous cell carcinomas, whereas continuous blockade did not produce the same effect. Their work established that the duration of opioid receptor blockade—not the average serum drug concentration—determines the proliferative response. This dose- and timing-dependent biology is the conceptual foundation for the “low-dose” designation: brief, intermittent blockade is functionally distinct from sustained, full blockade.

3.2. Non-opioid anti-inflammatory actions

In addition to opioid receptor modulation, naltrexone—particularly its (+)-isomer—antagonizes TLR4 signaling on microglia, macrophages, and other myeloid lineage cells. Hutchinson and colleagues (2008) demonstrated non-stereoselective reversal of neuropathic pain by naloxone and naltrexone, implicating TLR4 signaling in opioid antagonist analgesia. Subsequent work by the same group documented that opioid antagonists attenuate glial activation, reduce production of pro-inflammatory cytokines including TNF-α and IL-6, and decrease nitric oxide-mediated neurotoxicity (Hutchinson, Bland, Johnson, Rice, Maier, & Watkins, 2007). These effects appear to underlie much of LDN’s utility in chronic inflammatory and central sensitization syndromes, including those involving the gut–brain axis.

3.3. The OGF–OGFr axis

A third major mechanism—particularly relevant to gastrointestinal applications—involves the opioid growth factor (OGF), also known as [Met⁵]-enkephalin, and its dedicated receptor OGFr. The OGF–OGFr axis is a tonically active inhibitory pathway regulating cellular proliferation in normal and neoplastic tissues. Intermittent blockade of OGFr by LDN upregulates expression of both OGF and OGFr at the translational level, enhancing the activity of this axis once the blockade dissipates (Donahue et al., 2011; Zagon, Donahue, McLaughlin, & Smith, 2011). The functional consequence is a modulation of cell proliferation that can be either growth-inhibitory in neoplastic settings or pro-reparative in tissue injury, depending on the cellular and inflammatory context. Subsequent work has implicated the OGF–OGFr axis in the regulation of autoimmune disease, including experimental autoimmune encephalomyelitis, with parallels to multiple sclerosis and other chronic inflammatory conditions (Zagon & McLaughlin, 2018).

4. Mechanisms of Action in the Gastrointestinal Tract

The gastrointestinal tract integrates several of the mechanistic pathways through which LDN is thought to act. The following sections review the principal mechanisms relevant to gastrointestinal applications.

4.1. Opioid receptors and the enteric nervous system

Opioid receptors are densely expressed throughout the gastrointestinal tract on enteric neurons, immune cells, epithelial cells, and smooth muscle. Endogenous opioids participate in regulation of motility, secretion, nociception, mucosal immunity, and epithelial repair. Activation of μ-opioid receptors slows intestinal transit and reduces fluid secretion—the well-recognized basis for the constipating effects of conventional opioid analgesics. Transient blockade through LDN, in contrast, may alter enteric signaling in ways that normalize dysregulated motility and visceral pain perception. Ploesser, Weinstock, and Thomas (2010) reported clinical use of LDN for facilitation of migrating motor complex activity in patients with SIBO, providing observational support for a prokinetic role in patients with hypomotility, a hypothesis consistent with the known effects of opioid antagonism on intestinal transit.

4.2. The OGF–OGFr axis and mucosal repair

The OGF–OGFr axis is particularly relevant to mucosal repair in the gastrointestinal tract. Bedtime LDN dosing produces a window of receptor blockade of several hours followed by approximately eighteen to twenty hours of upregulated endogenous opioid signaling, during which OGF and OGFr can interact to influence cellular proliferation, tissue repair, and immune regulation (Donahue et al., 2011; Zagon et al., 2011). In the context of IBD, where mucosal healing has become a central treatment goal, this mechanism provides a biologically coherent explanation for the endoscopic responses observed in clinical trials.

4.3. TLR4 antagonism and the modulation of neuroinflammation

TLR4 is expressed on intestinal epithelial cells, dendritic cells, macrophages, enteric glia, and microglia. Persistent activation by LPS or damage-associated molecular patterns drives downstream NF-κB signaling, cytokine release, and oxidative stress. By antagonizing TLR4 signaling, LDN attenuates the inflammatory cascade implicated in increased intestinal permeability, mucosal inflammation, dysbiosis, visceral hypersensitivity, and central sensitization (Hutchinson et al., 2007, 2008). The implications extend beyond the gut: dampening neuroinflammatory signaling along the gut–brain axis may contribute to the symptomatic improvements LDN-treated patients frequently report in fatigue, sleep, pain amplification, and cognitive symptoms.

4.4. Enteric glia, visceral hypersensitivity, and central sensitization

Enteric glial cells, structurally and functionally analogous to astrocytes in the central nervous system, are increasingly recognized as central regulators of intestinal homeostasis. Activated enteric glia release pro-inflammatory cytokines, chemokines, and reactive oxygen species that sensitize enteric neurons, promote epithelial barrier dysfunction, and amplify visceral nociception. Through its effects on opioid signaling and TLR4 activity, LDN appears to dampen glial activation, providing a mechanistic basis for the symptomatic improvement reported in IBS, fibromyalgia-associated gastrointestinal symptoms, and other central sensitization syndromes (Patten et al., 2018).

4.5. Mucosal barrier function and endoplasmic reticulum stress

Lie and colleagues (2018) provided important translational evidence that LDN exerts direct effects on the intestinal epithelium. In human intestinal epithelial cell lines and patient-derived intestinal organoids, naltrexone improved wound healing in scratch-assay models and reduced endoplasmic reticulum (ER) stress induced by LPS, tunicamycin, and live bacteria. Inflamed mucosa from IBD patients showed elevated ER stress markers (GRP78 and CHOP), which were reduced in patients treated with LDN. These findings demonstrate that LDN can act on the epithelial barrier itself, independent of systemic immunomodulation, supporting its role in conditions characterized by barrier dysfunction.

4.6. Effects on motility and the migrating motor complex

Beyond its anti-inflammatory effects, LDN has been postulated to act as a mild prokinetic agent through release of tonic opioid inhibition on the migrating motor complex (MMC), the cyclical pattern of motor activity that clears the small intestine between meals. Impaired MMC function is mechanistically linked to SIBO recurrence, and integrative gastroenterologists have employed LDN in this setting based on its observed effects in clinical practice (Ploesser et al., 2010). Although randomized prokinetic data specific to LDN are lacking, the mechanistic rationale is consistent with the known effects of opioid antagonism on intestinal transit.

5. Low-Dose Naltrexone in Inflammatory Bowel Disease

5.1. Pathophysiology and unmet clinical need

Inflammatory bowel disease, encompassing Crohn’s disease and ulcerative colitis, is a chronic, relapsing immune-mediated inflammation of the gastrointestinal tract. Despite substantial advances in biologic and small-molecule therapy—including anti-TNF agents, anti-integrins, anti-interleukin-12/23 agents, and Janus kinase inhibitors—approximately thirty percent of patients are refractory to current therapies or lose response over time (Lie et al., 2018). Many patients experience persistent symptoms, medication intolerance, or incomplete remission, and a significant minority face progressive complications including fistulas, strictures, and the need for surgical intervention. The unmet clinical need has driven interest in well-tolerated adjunctive therapies that may improve symptomatic and endoscopic outcomes without the immunosuppressive risks of conventional agents.

5.2. Crohn’s disease: early clinical evidence

5.2.1. The Smith open-label pilot trial (2007)

The first clinical investigation of LDN in Crohn’s disease was an open-label pilot trial reported by Smith and colleagues (2007). Seventeen adults with histologically and endoscopically confirmed active Crohn’s disease and a Crohn’s Disease Activity Index (CDAI) score between 220 and 450 received LDN 4.5 mg nightly for twelve weeks while continuing prior stable therapy. Eighty-nine percent of participants exhibited a clinical response, sixty-seven percent achieved remission (p < 0.001), and significant improvements were noted on both the Inflammatory Bowel Disease Questionnaire and the SF-36 quality of life survey. Sleep disturbance was the most common side effect. The investigators concluded that LDN was effective and safe and warranted further controlled investigation.

5.2.2. The Smith randomized placebo-controlled trial (2011)

Smith and colleagues (2011) subsequently conducted a randomized, double-blind, placebo-controlled trial in forty adults with moderate-to-severe active Crohn’s disease, allocating eighteen patients to LDN 4.5 mg nightly and sixteen to placebo for twelve weeks. The primary outcome was the proportion of subjects with a 70-point decline in CDAI from baseline. Eighty-eight percent of LDN-treated patients achieved at least a 70-point CDAI decline compared with forty percent of placebo-treated patients (p = 0.009). Endoscopic response, defined as a 5-point decline in the Crohn’s Disease Endoscopy Index of Severity (CDEIS), was achieved by seventy-eight percent of LDN patients versus twenty-eight percent of placebo patients (p = 0.008), and endoscopic remission (CDEIS < 6) was achieved in thirty-three percent versus eight percent. Fatigue was the only adverse event reported significantly more often in the placebo arm. The investigators concluded that LDN promotes mucosal healing in active Crohn’s disease.

5.2.3. Pediatric Crohn’s disease (Smith et al., 2013)

Smith and colleagues (2013) extended their investigations to pediatric Crohn’s disease in a randomized double-blind trial enrolling fourteen children, mean age 12.3 years, with moderate-to-severe disease. Children received naltrexone 0.1 mg/kg (maximum 4.5 mg) or placebo orally for eight weeks, followed by an eight-week open-label extension. Naltrexone was well tolerated without serious adverse events. The Pediatric CDAI declined significantly from a mean baseline of 34.2 to 21.7 (p = 0.005). Twenty-five percent of treated children achieved remission (PCDAI ≤ 10), and sixty-seven percent improved to mild disease activity. Quality of life improved significantly on the Impact III survey. The investigators concluded that LDN therapy appears safe with limited toxicity in pediatric Crohn’s disease and may reduce disease activity.

5.3. Real-world evidence from prospective and database studies

5.3.1. The Lie prospective cohort (2018)

Lie and colleagues (2018) prospectively followed forty-seven adult patients with therapy-refractory IBD (Crohn’s disease and ulcerative colitis) treated with LDN 4.5 mg nightly for twelve weeks. Of the forty-seven patients, thirty-five (74.5%) achieved a clinical response. Twelve patients (25.5%) sustained response for at least three months (eight with Crohn’s disease, four with ulcerative colitis), while the remaining twenty-three experienced short-lived improvement of four to twelve weeks. There was no significant difference between Crohn’s disease and ulcerative colitis in response or remission rates. Among patients with paired endoscopies, those in clinical remission showed significant reductions in endoscopic inflammation scores. Adverse events were reported in 14.9% of patients, primarily vivid dreams, drowsiness, and headache; two patients discontinued therapy for drowsiness. The investigators concluded that LDN therapy is effective and safe in selected therapy-refractory IBD patients and may be considered as an adjunctive option.

5.3.2. Norwegian prescription database (Raknes et al., 2018)

Raknes, Simonsen, and Småbrekke (2018) conducted a quasi-experimental before-and-after analysis using the Norwegian Prescription Database following a sudden increase in LDN use in Norway in 2013. They identified 582 IBD patients with at least one LDN prescription and analyzed dispensing of conventional IBD medications before and after LDN initiation. Cumulative defined daily doses of IBD drugs declined significantly in the 730 days after initiation of LDN compared with the 730 days before, with reductions observed in systemic immunosuppressants and intestinal anti-inflammatory agents in both Crohn’s disease and ulcerative colitis populations. The investigators acknowledged that the design cannot establish causality but argued that the findings are consistent with a beneficial effect of LDN sufficient to allow reduction of conventional medications, while not excluding other explanations such as regression to the mean.

5.4. Ulcerative colitis

5.4.1. The Weinstock UC case series (2014)

Evidence specific to ulcerative colitis is more limited than for Crohn’s disease. Weinstock (2014) reported a retrospective chart review of twelve adults with moderate-to-severe ulcerative colitis who had failed or had partial response to mercaptopurine and/or infliximab and received adjunctive LDN 4.5 mg daily. Mean duration of LDN therapy was 46 ± 75 weeks, with a maximum of 270 weeks. One patient withdrew at eight weeks due to insomnia. Positive clinical responses (markedly or moderately improved) were reported in six of twelve patients (50%). Two clinical responders underwent colonoscopy before and after LDN therapy and both showed complete mucosal healing. Weinstock concluded that adjunctive LDN appears effective in some ulcerative colitis patients failing conventional therapy.

5.4.2. Pediatric duodenal Crohn’s disease (Shannon et al., 2010)

Shannon, Alkhouri, Mayacy, Kaplan, and Mahajan (2010) reported a single pediatric case of duodenal Crohn’s disease responsive to LDN, demonstrating that the proposed mechanisms may extend to less commonly involved regions of the gastrointestinal tract.

5.4.3. Recent clinical case reports (Weinstock, 2022)

More recently, Weinstock (2022) presented two case reports of patients with symptomatic Crohn’s disease who exhibited rapid clinical and endoscopic responses to LDN: one with Crohn’s colitis previously failing mesalamine and mercaptopurine, who entered prolonged endoscopic remission on LDN plus mesalamine; and one with Crohn’s ileitis maintained in remission for several years on a combination of infliximab, methotrexate, and LDN. These cases underscore the potential role of LDN as adjunctive therapy in combination with biologic and immunomodulatory regimens.

5.5. Cochrane systematic review and evidence quality

Parker, Nguyen, Segal, MacDonald, and Chande (2018) conducted a Cochrane systematic review of randomized controlled trials of LDN for induction of remission in Crohn’s disease, identifying two studies with a total of 46 participants (the Smith 2011 adult trial and the Smith 2013 pediatric trial). Both studies were judged to have a low risk of bias. In the adult trial reanalyzed on intention-to-treat, eighty-three percent (15/18) of LDN patients achieved a 70-point clinical response at twelve weeks compared with thirty-eight percent (6/16) of placebo patients (RR 2.22; 95% CI 1.14–4.32). Seventy-two percent (13/18) of LDN patients achieved an endoscopic response compared with twenty-five percent (4/16) of placebo patients (RR 2.89; 95% CI 1.18–7.08). Differences in clinical remission and endoscopic remission did not reach statistical significance, and confidence intervals were wide because of small sample size. Pooled data showed no significant differences in withdrawals due to adverse events or in specific adverse events compared with placebo. The overall quality of evidence was rated as low using GRADE criteria, predominantly because of imprecision related to sparse data. The investigators concluded that current evidence is insufficient to permit firm conclusions about the efficacy and safety of LDN in active Crohn’s disease but is suggestive enough to justify further trials.

5.6. Ongoing trials

The LDN Crohn study (Lie et al., 2022), a randomized, double-blind, placebo-controlled multicenter trial sponsored by the Erasmus University Medical Center, is currently enrolling adults with mild-to-moderate Crohn’s disease (SES-CD 3–15) and randomizing participants 1:1 to LDN 4.5 mg nightly or matched placebo for twelve weeks. The primary outcome is endoscopic remission at week twelve. The study is powered at 85% to detect a true difference in the primary outcome with sixty-one patients per arm. Permitted concomitant therapies include aminosalicylates, thiopurines, methotrexate, and tapering oral corticosteroids, reflecting a pragmatic real-world design. The results of this trial, when available, will substantially clarify the role of LDN in mild-to-moderate Crohn’s disease.

5.7. Mechanistic synthesis in IBD

Across mechanistic and clinical studies, the proposed actions of LDN in IBD include suppression of TLR4-mediated inflammation, reduction in pro-inflammatory cytokine production, enhancement of endogenous opioid and OGF–OGFr signaling, promotion of epithelial repair through reduction of ER stress, modulation of enteric glial activation, and improvement in intestinal barrier function (Lie et al., 2018; Zagon et al., 2011). The convergence of these mechanisms with the clinical observation of improved symptoms and mucosal healing provides a coherent if still incomplete picture of why LDN may be of benefit in IBD.

6. Low-Dose Naltrexone in Irritable Bowel Syndrome

6.1. Pathophysiology of IBS and the rationale for LDN

Irritable bowel syndrome is a functional gastrointestinal disorder defined by recurrent abdominal pain associated with altered bowel habits. The pathophysiology is multifactorial, involving visceral hypersensitivity, altered gut–brain signaling, dysbiosis, low-grade mucosal immune activation, post-infectious changes, and central sensitization. Many IBS patients also exhibit overlapping conditions—fibromyalgia, chronic fatigue syndrome, migraine, mast cell activation syndrome, postural orthostatic tachycardia syndrome (POTS), and various autoimmune disorders—each sharing mechanisms involving neuroinflammation and central sensitization. Because LDN appears capable of modulating both neuroinflammatory signaling and visceral pain pathways, it has been investigated as a candidate therapy in IBS.

6.2. The Kariv open-label pilot study (2006)

Kariv and colleagues (2006) conducted an open-label single-arm pilot study evaluating very-low-dose naltrexone (PTI-901, 0.5 mg/day) administered for four weeks in forty-two patients with IBS. The investigators reported a global symptom improvement in seventy-six percent of participants, with a statistically significant increase in the mean weekly number of pain-free days (from 0.5 ± 1 to 1.25 ± 2.14; p = 0.011) and a favorable side-effect profile. The investigators concluded that a larger, randomized, double-blind, placebo-controlled trial of PTI-901 was justified. To date, no such pivotal trial has been reported, and the Kariv pilot remains the only published prospective study specifically evaluating LDN in IBS.

6.3. The Ploesser observational study (2010)

Ploesser, Weinstock, and Thomas (2010) conducted a retrospective survey of 206 patients in a gastroenterology practice prescribed LDN for IBS without SIBO, IBS with SIBO, chronic idiopathic constipation, or IBD. Patients with diarrhea-predominant phenotypes received LDN 2.5 mg daily, those with constipation-predominant phenotypes received 2.5 mg twice daily, and those with IBD received 4.5 mg daily. Among the 121 survey respondents, 38.8% reported no side effects, while 61.2% reported one or more adverse events; the most common were neurological complaints (e.g., insomnia, vivid dreams, headache) followed by gastrointestinal symptoms. Adverse events were short-lived in approximately one-third of patients, and 27% discontinued LDN due to side effects. Among eighty-five patients with IBS-SIBO, fifteen were markedly improved, while a substantial fraction reported worsening. Among twelve patients with chronic constipation, seven were markedly improved. Although limited by survey methodology and selection bias, this study provided early observational evidence that LDN may be useful in a subset of patients with functional GI disorders, while also highlighting that careful titration and patient selection are essential.

6.4. Hypothesized mechanisms and patient phenotypes

Hypothesized mechanisms of benefit in IBS include reductions in visceral hypersensitivity through modulation of enteric and central glial activation, attenuation of low-grade mucosal inflammation, normalization of motility patterns through opioid antagonism, and improvements in sleep architecture and central pain processing. Patients with overlapping fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome, POTS, or other central sensitization syndromes may represent a particularly responsive subgroup, given the shared mechanisms involving central sensitization and neuroimmune dysregulation. However, definitive evidence of efficacy in IBS remains limited, and adequately powered randomized controlled trials with standardized endpoints are needed to establish responder phenotypes and optimal dosing strategies.

7. Low-Dose Naltrexone, Dysbiosis, SIBO, and Functional Dysmotility

7.1. SIBO and the central role of motility

Small intestinal bacterial overgrowth (SIBO) involves excessive bacterial colonization of the small intestine and is associated with bloating, abdominal discomfort, diarrhea or constipation, nutrient malabsorption, and a range of systemic symptoms. SIBO is mechanistically linked to impaired migrating motor complex activity, anatomic alterations, immune dysfunction, and altered host–microbiome interactions. Although antibiotic therapy with rifaximin or other agents is the mainstay of treatment, recurrence is common, and effective prokinetic strategies remain a clinical priority.

7.2. LDN as adjunctive therapy in SIBO and dysbiosis

Although LDN is not an antimicrobial agent, several mechanisms suggest a possible adjunctive role in SIBO and dysbiosis-related disorders. Through release of tonic opioid inhibition on enteric neurons, LDN may improve MMC activity and intestinal transit; through attenuation of TLR4-mediated mucosal inflammation, it may reduce immune activation that contributes to motility dysfunction; and through modulation of intestinal barrier function and neuroinflammatory signaling, it may improve the broader gut–brain axis dysregulation that frequently accompanies recurrent SIBO. Ploesser et al. (2010) described observational benefit in a subset of SIBO patients using 2.5 mg twice daily, with approximately one-third experiencing notable improvement. Clinical experience suggests that LDN can be a useful component of integrative SIBO management, particularly in patients with comorbid mast cell activation, POTS, autoimmune disease, or central sensitization syndromes.

7.3. Limitations and patient selection

Evidence for LDN in SIBO and dysbiosis remains largely observational. Some patients—particularly those with mast cell activation, histamine intolerance, or significant dysautonomia—experience transient worsening of bloating, abdominal discomfort, or altered bowel habits during dose escalation. Careful titration, individualized starting doses, and integration with established management strategies (including dietary modification, targeted antimicrobial therapy, evidence-based prokinetics, and treatment of underlying contributors such as ileocecal valve dysfunction or anatomic predispositions) are essential. LDN should be regarded as an adjunctive tool rather than a primary therapy in SIBO.

8. Low-Dose Naltrexone and the Gut–Brain Axis

8.1. The gut–brain axis in chronic gastrointestinal disease

The gut–brain axis comprises bidirectional communication between the gastrointestinal tract, the enteric and autonomic nervous systems, the immune system, and the central nervous system. Disruptions in this network contribute to IBS, functional dyspepsia, chronic nausea, visceral hypersensitivity, anxiety-associated gastrointestinal symptoms, and dysautonomia-related bowel dysfunction. Neuroinflammation and glial activation are increasingly recognized as central drivers of chronic pain and central sensitization, and the gut is now appreciated as a key site of origin and amplification for these processes.

8.2. Overlap syndromes: MCAS, POTS, fibromyalgia, and CFS

Patients with central sensitization syndromes—including mast cell activation syndrome (MCAS), POTS, fibromyalgia, chronic fatigue syndrome, and Long COVID—frequently present with gastrointestinal symptoms including IBS-like patterns, dysmotility, food sensitivities, and recurrent SIBO. These overlap syndromes share mechanisms involving neuroimmune dysregulation, mast cell activation, autonomic dysfunction, and central sensitization—precisely the pathways that LDN is hypothesized to modulate. Although controlled data in these subpopulations are limited, clinical experience and the broader literature on LDN in fibromyalgia and other central sensitization syndromes provide a coherent rationale for its use as an adjunctive therapy when gastrointestinal symptoms are part of a wider neuroinflammatory presentation (Patten et al., 2018).

8.3. Systemic effects relevant to GI symptom improvement

Patients on LDN frequently report improvements in sleep quality, fatigue, anxiety, pain amplification, cognitive symptoms (commonly described as “brain fog”), and overall stress tolerance. These broader systemic effects may contribute meaningfully to gastrointestinal symptom improvement in functional disorders, even where direct effects on motility or mucosal inflammation are modest. Endogenous opioids also modulate mood, stress resilience, and autonomic function, and the upregulation of endogenous opioid tone associated with LDN therapy may indirectly improve gastrointestinal symptoms through modulation of stress-related autonomic dysregulation.

9. Practical Clinical Considerations

9.1. Patient selection

Selecting patients for LDN therapy in a gastrointestinal context requires consideration of the underlying diagnosis, prior treatment response, concomitant medications, and individual sensitivity. Patients most likely to benefit include those with mild-to-moderate Crohn’s disease as adjunctive therapy, ulcerative colitis with partial response to conventional treatment, IBS with prominent visceral hypersensitivity or pain features, recurrent SIBO with documented dysmotility, and functional GI disorders accompanying central sensitization syndromes. Concurrent use of full-agonist or partial-agonist opioid analgesics is a contraindication because of the risk of precipitated withdrawal and loss of analgesic efficacy, and severe hepatic impairment warrants caution.

9.2. Dosing and titration

LDN is typically initiated at low doses and titrated gradually to improve tolerability. A common starting regimen is 0.5 to 1.5 mg taken nightly, with gradual upward titration every one to two weeks toward a typical target dose of 3.0 to 4.5 mg nightly. In IBD, the 4.5 mg nightly dose has been used in most clinical trials; in IBS, doses of 0.5 mg to 4.5 mg have been used; in SIBO with constipation-predominant features, divided dosing of 2.5 mg twice daily has been described (Ploesser et al., 2010). Compounding pharmacies are required because no commercial formulation of LDN is available, and immediate-release capsules or oral liquid formulations are preferred to slow-release preparations, which may not produce the transient receptor blockade that underlies the therapeutic effect.

9.3. Sensitive patient populations

Patients with heightened sensitivity—including those with mast cell activation syndrome, severe dysautonomia, fibromyalgia, mold-related illness, or significant autoimmune disease—may require ultra-low-dose initiation (for example, 0.1 to 0.25 mg) and slower titration. In these patients, transient flares of symptoms during dose escalation are common and often respond to dose reduction with subsequent reattempt at lower increments. Patient education about the expected timeline of response (often six to twelve weeks or longer) and the relatively common transient sleep disturbances or vivid dreams improves adherence and reduces premature discontinuation.

9.4. Monitoring and outcome measures

Useful clinical monitoring parameters include abdominal pain intensity and frequency, stool frequency and consistency, bloating, sleep quality, fatigue, food tolerance, extraintestinal symptoms (especially in IBD), and selected inflammatory biomarkers when clinically indicated. In IBD, fecal calprotectin and C-reactive protein can be used to monitor objective inflammation, and follow-up endoscopy at three to six months after initiation may be appropriate to assess mucosal response. In IBS and SIBO, validated symptom scales (e.g., IBS-SSS, IBS-QoL) and breath testing where indicated can provide objective monitoring data.

9.5. Combination with conventional therapy

Across the published literature and clinical experience, LDN has been most commonly used as an adjunct to existing conventional therapy rather than as monotherapy. The clinical trial literature in Crohn’s disease has typically allowed continuation of stable doses of aminosalicylates, thiopurines, methotrexate, biologic agents, and tapering corticosteroids. Recent case reports have described favorable outcomes when LDN is combined with infliximab, methotrexate, or other immunomodulatory regimens (Weinstock, 2022). The Norwegian database study (Raknes et al., 2018) suggests that adjunctive LDN may permit reduction of conventional medication use over time. Decisions about discontinuation or de-escalation of conventional therapy should be made cautiously and in consultation with the patient’s gastroenterologist.

10. Safety and Adverse Effects

LDN is generally well tolerated, with a safety profile considerably more favorable than that of most conventional immunosuppressive or biologic therapies used in IBD. The most commonly reported adverse effects across published studies include vivid dreams, transient insomnia, headache, fatigue, anxiety, and transient gastrointestinal symptoms (bloating, nausea, abdominal cramping, altered bowel habits). The majority of these are transient and improve with slower titration or temporary dose reduction (Patten et al., 2018; Ploesser et al., 2010). In the Cochrane meta-analysis of Crohn’s disease trials, pooled data showed no significant differences between LDN and placebo in withdrawals due to adverse events or in any specific adverse event, and no serious adverse events were reported in either of the included studies (Parker et al., 2018).

Concurrent use of full-agonist or partial-agonist opioid analgesics is contraindicated because of the risk of precipitated withdrawal and loss of analgesic efficacy. Patients should be counseled to discontinue LDN at least seventy-two hours before any planned surgical procedure that may require opioid analgesia, and to inform any treating clinicians about ongoing LDN use. Caution is appropriate in patients with severe hepatic impairment, given that naltrexone is primarily metabolized by the liver. Although long-term safety data specific to LDN remain limited, the cumulative experience over more than three decades of clinical use, combined with prospective and observational studies, supports a favorable safety profile for chronic administration.

11. Limitations of the Current Evidence Base

Despite the consistency of mechanistic and clinical findings, the evidence base for LDN in gastrointestinal disorders remains limited in important respects. First, the number of randomized controlled trials is small, and the studies that exist are relatively underpowered. The Cochrane systematic review identified only two randomized trials in Crohn’s disease, totaling forty-six participants, and the overall quality of evidence was rated as low (Parker et al., 2018). Second, no large randomized trials have been reported for ulcerative colitis or IBS specifically, and evidence in these conditions remains largely observational. Third, heterogeneity in dosing strategies, patient selection, outcome measures, and concomitant therapy across studies complicates comparison and meta-analysis. Fourth, the mechanistic literature, while compelling, is dominated by a small number of research groups, and independent replication of key findings—particularly regarding the OGF–OGFr axis and TLR4 antagonism in human gastrointestinal disease—remains limited. Fifth, long-term safety and durability data are sparse, particularly for pediatric patients and for combination use with biologic agents.

These limitations argue for caution in interpreting the evidence base, but they should not be taken as evidence of inefficacy. The relatively favorable safety profile of LDN, the convergence of mechanistic and clinical findings, and the persistent unmet clinical need in IBD, IBS, and functional gastrointestinal disorders justify continued investigation and judicious clinical use.

12. Future Directions

Several priorities for future research stand out. The most important is the completion and publication of adequately powered randomized controlled trials in IBD, particularly the ongoing LDN Crohn study and analogous studies in ulcerative colitis. Additional priorities include adequately powered randomized trials in IBS with standardized endpoints (e.g., FDA-recognized composite endpoints for IBS-D and IBS-C); microbiome-focused investigations using next-generation sequencing and metabolomics to clarify host–microbiome effects of LDN; identification of biomarkers predictive of treatment response, including cytokine profiles, mucosal gene expression, fecal calprotectin trajectories, and microbiome signatures; long-term safety and pharmacovigilance studies, particularly in pediatric and combination-therapy settings; mechanistic investigations using intestinal organoid models and single-cell transcriptomics to clarify direct effects of LDN on epithelial and immune populations; and precision medicine approaches that stratify patients by inflammatory phenotype, comorbidity profile, or pharmacogenomic characteristics. As the understanding of neuroimmune interactions within the gut continues to evolve, LDN may ultimately occupy a distinctive therapeutic niche at the intersection of immunology, neurology, microbiome science, and integrative gastroenterology.

13. Conclusion

Low-dose naltrexone represents a promising adjunctive therapy for selected gastrointestinal disorders characterized by immune dysregulation, neuroinflammation, visceral hypersensitivity, and barrier dysfunction. Mechanistic data indicate that LDN influences endogenous opioid signaling, the OGF–OGFr axis, TLR4-mediated inflammation, enteric glial activation, mucosal repair, ER stress responses, and gut–brain communication. The clinical evidence is most developed in Crohn’s disease, where small randomized and pilot trials have demonstrated symptomatic improvement and endoscopic healing; ulcerative colitis case series and prospective cohort data suggest similar benefit; and observational data in IBS, SIBO, and gut–brain axis disorders support continued investigation.

Although the current evidence base remains preliminary and the overall quality of evidence in IBD has been rated as low because of imprecision and small sample sizes, the consistency of mechanistic and clinical findings, the relatively favorable safety profile, and the unmet clinical need in this population justify the continued cautious use of LDN as an adjunctive therapy. Larger and more rigorous controlled studies are needed to clarify efficacy, optimize dosing, elucidate mechanisms, and identify the patient populations most likely to benefit. At present, LDN should be considered an integrative adjunct rather than a replacement for evidence-based conventional therapy, with careful patient selection, individualized dosing, ongoing clinical monitoring, and informed consent as essential elements of responsible use.

References

Abraham, C., & Cho, J. H. (2009). Inflammatory bowel disease. The New England Journal of Medicine, 361(21), 2066–2078. https://doi.org/10.1056/NEJMra0804647

Donahue, R. N., McLaughlin, P. J., & Zagon, I. S. (2011). Low-dose naltrexone targets the opioid growth factor–opioid growth factor receptor pathway to inhibit cell proliferation: Mechanistic evidence from a tissue culture model. Experimental Biology and Medicine, 236(9), 1036–1050. https://doi.org/10.1258/ebm.2011.011121

Furness, J. B. (2012). The enteric nervous system and neurogastroenterology. Nature Reviews Gastroenterology & Hepatology, 9(5), 286–294. https://doi.org/10.1038/nrgastro.2012.32

Hutchinson, M. R., Bland, S. T., Johnson, K. W., Rice, K. C., Maier, S. F., & Watkins, L. R. (2007). Opioid-induced glial activation: Mechanisms of activation and implications for opioid analgesia, dependence, and reward. The Scientific World Journal, 7, 98–111. https://doi.org/10.1100/tsw.2007.230

Hutchinson, M. R., Zhang, Y., Brown, K., Coats, B. D., Shridhar, M., Sholar, P. W., Patel, S. J., Crysdale, N. Y., Harrison, J. A., Maier, S. F., Rice, K. C., & Watkins, L. R. (2008). Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone implicates Toll-like receptor 4 signaling. European Journal of Neuroscience, 28(1), 20–29. https://doi.org/10.1111/j.1460-9568.2008.06321.x

Kariv, R., Tiomny, E., Grenshpon, R., Dekel, R., Waisman, G., Ringel, Y., & Halpern, Z. (2006). Low-dose naltreoxone for the treatment of irritable bowel syndrome: A pilot study. Digestive Diseases and Sciences, 51(12), 2128–2133. https://doi.org/10.1007/s10620-006-9289-8

Lie, M. R. K. L., van der Giessen, J., Fuhler, G. M., de Lima, A., Peppelenbosch, M. P., van der Ent, C., van der Woude, C. J., & Te Velde, A. A. (2018). Low dose naltrexone for induction of remission in inflammatory bowel disease patients. Journal of Translational Medicine, 16(1), 55. https://doi.org/10.1186/s12967-018-1427-5

Lie, M. R. K. L., Kreijne, J. E., Dijkstra, G., Löwenberg, M., van Bodegraven, A. A., West, R. L., Oldenburg, B., Pierik, M. J., van der Marel, S., van der Meulen-de Jong, A. E., Romkens, T. E. H., van Tuyl, B. A. C., Boekema, P. J., van Hogezand, R. A., Peppelenbosch, M. P., Fuhler, G. M., & van der Woude, C. J. (2022). Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn’s disease: Protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study. BMJ Open, 12(4), e058358. https://doi.org/10.1136/bmjopen-2021-058358

Parker, C. E., Nguyen, T. M., Segal, D., MacDonald, J. K., & Chande, N. (2018). Low dose naltrexone for induction of remission in Crohn’s disease. Cochrane Database of Systematic Reviews, 2018(4), CD010410. https://doi.org/10.1002/14651858.CD010410.pub3

Patten, D. K., Schultz, B. G., & Berlau, D. J. (2018). The safety and efficacy of low-dose naltrexone in the management of chronic pain and inflammation in multiple sclerosis, fibromyalgia, Crohn’s disease, and other chronic pain disorders. Pharmacotherapy, 38(3), 382–389. https://doi.org/10.1002/phar.2086

Ploesser, J., Weinstock, L. B., & Thomas, E. (2010). Low dose naltrexone: Side effects and efficacy in gastrointestinal disorders. International Journal of Pharmaceutical Compounding, 14(2), 171–173. PMID: 23965429.

Raknes, G., Simonsen, P., & Småbrekke, L. (2018). The effect of low-dose naltrexone on medication in inflammatory bowel disease: A quasi experimental before-and-after prescription database study. Journal of Crohn’s and Colitis, 12(6), 677–686. https://doi.org/10.1093/ecco-jcc/jjy008

Shannon, A., Alkhouri, N., Mayacy, S., Kaplan, B., & Mahajan, L. (2010). Low-dose naltrexone for treatment of duodenal Crohn’s disease in a pediatric patient. Inflammatory Bowel Diseases, 16(9), 1457. https://doi.org/10.1002/ibd.21185

Smith, J. P., Stock, H., Bingaman, S., Mauger, D., Rogosnitzky, M., & Zagon, I. S. (2007). Low-dose naltrexone therapy improves active Crohn’s disease. The American Journal of Gastroenterology, 102(4), 820–828. https://doi.org/10.1111/j.1572-0241.2007.01045.x

Smith, J. P., Bingaman, S. I., Ruggiero, F., Mauger, D. T., Mukherjee, A., McGovern, C. O., & Zagon, I. S. (2011). Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn’s disease: A randomized placebo-controlled trial. Digestive Diseases and Sciences, 56(7), 2088–2097. https://doi.org/10.1007/s10620-011-1653-7

Smith, J. P., Field, D., Bingaman, S. I., Evans, R., & Mauger, D. T. (2013). Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn’s disease: A pilot study. Journal of Clinical Gastroenterology, 47(4), 339–345. https://doi.org/10.1097/MCG.0b013e3182702f2b

Weinstock, L. B. (2014). Naltrexone therapy for Crohn’s disease and ulcerative colitis. Journal of Clinical Gastroenterology, 48(8), 742. https://doi.org/10.1097/MCG.0000000000000093

Weinstock, L. B. (2022). Efficacy of low dose naltrexone in patients with Crohn’s colitis and ileitis. Inflammatory Bowel Diseases, 28(Suppl. 1), S106–S107. https://doi.org/10.1093/ibd/izac015.172

Younger, J., Parkitny, L., & McLain, D. (2014). The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clinical Rheumatology, 33(4), 451–459. https://doi.org/10.1007/s10067-014-2517-2

Zagon, I. S., Donahue, R. N., McLaughlin, P. J., & Smith, J. P. (2011). Opioid growth factor and low dose naltrexone: Endogenous regulators of cell proliferation in cancer and autoimmune disease. Current Pharmaceutical Design, 17(29), 3126–3135. https://doi.org/10.2174/138161211798157603

Zagon, I. S., & McLaughlin, P. J. (2018). Intermittent blockade of OGFr and treatment of autoimmune disorders. Experimental Biology and Medicine, 243(17–18), 1323–1330. https://doi.org/10.1177/1535370218817746

About the Author

Yoon Hang “John” Kim, MD, MPH is a board-certified physician with more than 20 years of experience in preventive, integrative, and functional medicine. He completed the Fellowship in Integrative Medicine at the University of Arizona under Dr. Andrew Weil, where he served as an Osher Fellow, and holds certifications in preventive medicine, medical acupuncture (UCLA), and integrative/holistic medicine. He is an IFM Scholar and a nationally recognized clinician and educator on low-dose naltrexone (LDN), specializing in autoimmune disease, chronic pain, integrative oncology, fibromyalgia, chronic fatigue syndrome, mast cell activation syndrome, and mold-related illness. Dr. Kim is the author of three books and more than twenty articles, and founder of the LDN Support Group. Professional website: www.yoonhangkim.com | Clinical website: www.directintegrativecare.com.